Long-term (96 weeks) adefovir dipivoxil in HBeAg negative chronic hepatitis results in significant virological, biochemical and histological improvement.

被引：0
|
作者：
Hadziyannis, S
Tassopoulos, N
Heathcote, E
Chang, TT
Kitis, G
Rizzeto, M
Marcellin, P
Lim, SG
Chen, SS
Wulfsohn, M
Xiong, S
James, C
Currie, G
Brosgart, C
机构：
[1] Henry Dunant Hosp, Athens, M5T 2S8, Greece
[2] Western Attica Hosp, Athens, Greece
[3] Toronto Western Hosp, Toronto, ON, Canada
[4] Natl Cheng Kung Hosp, Taipei, Taiwan
[5] Georgios Papanikolaou Hosp, Thessaloniki, Greece
[6] Azienda Ospedaliera San Giovanni Battista, Turin 117548, Italy
[7] Hop Beaujon, Clichy, 94404, France
[8] Natl Univ Singapore, Singapore, Singapore
[9] Gilead Sci Inc, Foster City, CA USA
来源：
HEPATOLOGY | 2003年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
241
引用
收藏
页码：273A / 273A
页数：1
相关论文
共 50 条
  • [41] Long term treatment with adefovir dipivoxil (ADV) for three years in patients with lamivudine-resistant (LAM-R) HBV and HIV coinfection results in significant and sustained clinical improvement.
    Benhamou, Y
    Thibault, V
    Vig, P
    Valantin, MA
    Guyon, P
    Katlama, C
    Lu, B
    Currie, G
    Brosgart, C
    Poynard, T
    [J]. HEPATOLOGY, 2003, 38 (04) : 714A - 714A
  • [42] Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Marcellin, Patrick
    Chang, Ting-Tsung
    Lim, Seng G. Lee
    Sievert, William
    Tong, Myron
    Arterburn, Sarah
    Borroto-Esoda, Katyna
    Frederick, David
    Rousseau, Franck
    [J]. HEPATOLOGY, 2008, 48 (03) : 750 - 758
  • [43] DURABILITY OF ADEFOVIR DIPIVOXIL INDUCED HBEAG LOSS FOLLOWING LONG-TERM ADDITIONAL THERAPY IN PATIENTS WITH YMDD MUTANTS OF HEPATITIS B VIRUS
    Kim, Sung Eun
    Chung, Young-Hwa
    Kim, Jeong A.
    Lee, Yoon-Seon
    Lee, Danbi
    Lee, Sae Hwan
    Seo, Dong Dae
    Shin, Jung Woo
    Park, Neung Hwo
    Kim, Kang Mo
    Lee, Han Chu
    Lee, Yung Sang
    Suh, Dong Jin
    [J]. HEPATOLOGY, 2008, 48 (04) : 704A - 704A
  • [44] Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
    Hadziyannis, Stephanos J.
    Sevastianos, Vassilios
    Rapti, Irene
    Vassilopoulos, Dimitrios
    Hadziyannis, Emilia
    [J]. GASTROENTEROLOGY, 2012, 143 (03) : 629 - U115
  • [45] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Akarca, U.
    Hatzis, G.
    Kitis, G.
    Shouval, D.
    Lai, C.
    Cheinquer, H.
    Chang, T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    [J]. LIVER INTERNATIONAL, 2006, 26 : 5 - 5
  • [46] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Manns, M.
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S86 - S86
  • [47] Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients
    Manolakopoulos, Spilios
    Striki, Athanasia
    Deutsch, Melanie
    Mela, Maria
    Ketikoglou, Ioannis
    Tzourmakliotis, Dimitrios
    Manesis, Emanuel K.
    Papatheodoridis, George V.
    [J]. LIVER INTERNATIONAL, 2011, 31 (10) : 1525 - 1532
  • [48] Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
    Manalakopoulos, S.
    Bethanis, S.
    Koutsounas, S.
    Goulis, J.
    Vlachogiannakos, J.
    Christias, E.
    Savariadis, A.
    Pavlidis, C.
    Triantos, C.
    Christidou, A.
    Papatheodoridis, G.
    Karamanolis, D.
    Tzourmakliotis, D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (03) : 266 - 273
  • [49] Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R. G.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S36 - S36
  • [50] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Sollano, J.
    De Man, R. A.
    Mutimer, D.
    Gish, R. G.
    Chang, T. -T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    [J]. LIVER INTERNATIONAL, 2006, 26 : 6 - 7
12345